1. Folkman, J . Tumor angiogenesis: therapeutic implications[J]. N Engl J Med. 1971 Nov 18;285(21):1182-1186.
Google Scholar | Medline2. Folkman, J . What is the evidence that tumors are angiogenesis dependent?[J]. J Natl Cancer Inst. 1990 Jan 3;82(1):4-6.
Google Scholar | Crossref | Medline3. Folkman, J . Role of angiogenesis in tumor growth and metastasis[J]. Semin Oncol. 2002 Dec;29(6 Suppl 16):15-18.
Google Scholar | Medline4. Lugano, R, Ramachandran, M, Dimberg, A, et al. Tumor angiogenesis: causes, consequences, challenges and opportunities[J]. Cell Mol Life Sci. 2020 May;77(9):1745-1770.
Google Scholar | Crossref | Medline5. O'Reilly, MS, Boehm, T, Shing, Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth[J]. Cell. 1997 Jan 24;88(2):277-285.
Google Scholar | Crossref | Medline6. Folkman, J . Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action[J]. Exp Cell Res. 2006 Mar 10;312(5):594-607.
Google Scholar | Crossref | Medline7. Sim, BK, Fogler, WE, Zhou, XH, et al. Zinc ligand-disrupted recombinant human endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile[J]. Angiogenesis. 1999;3(1):41-51.
Google Scholar | Crossref | Medline8. Eder, JP, Supko, JG, Clark, JW, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily[J]. J Clin Oncol. 2002 Sep 15;20(18):3772-3784.
Google Scholar | Crossref | Medline9. Herbst, RS, Hess, KR, Tran, HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors[J]. J Clin Oncol. 2002 Sep 15;20(18):3792-3803.
Google Scholar | Crossref | Medline10. Thomas, JP, Arzoomanian, RZ, Alberti, D, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors[J]. J Clin Oncol. 2003 Jan 15;21(2):223-231.
Google Scholar | Crossref | Medline11. Hansma, AHG, Broxterman, HJ, van der Horst, I, et al. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer[J]. Ann Oncol. 2005 Oct;16(10):1695-1701.
Google Scholar | Crossref | Medline12. Kulke, MH, Bergsland, EK, Ryan, DP, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors[J]. J Clin Oncol. 2006 Aug 1;24(22):3555-3561.
Google Scholar | Crossref | Medline13. Mohajeri, A, Sanaei, S, Kiafar, F, et al. The challenges of recombinant endostatin in clinical application: focus on the different expression systems and molecular bioengineering[J]. Adv Pharm Bull. 2017 Apr;7(1):21-34.
Google Scholar | Crossref | Medline14. Fu, Y, Tang, H, Huang, Y, et al. Unraveling the mysteries of endostatin[J]. IUBMB Life. 2009 Jun;61(6):613-626.
Google Scholar | Crossref | Medline15. Li, K, Shi, M, Qin, S, et al. Current status and study progress of recombinant human endostatin in cancer treatment. Oncol Ther. 2018 Jun;6(1):21-43.
Google Scholar | Crossref | Medline16. Zhang, S, Han, C, Sun, L, et al. Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis[J]. Radiat Oncol. 2020 Aug 24;15(1):205.
Google Scholar | Crossref | Medline17. Zhang, K, Wang, Y, Yu, X, et al. Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth[J]. BMC Cancer. 2017 Dec 28;17(1):899.
Google Scholar | Crossref | Medline18. Zhang, X, Zhang, Z, Cao, M, et al. A randomized parallel controlled phase Ⅱ trial of recombinant human endostatin added to neoadjuvant chemotherapy for stage Ⅲ breast cancer[J]. Clin Breast Cancer. 2020 Aug;20(4):291-299.
Google Scholar | Crossref | Medline19. Moschos, SJ, Odoux, C, Land, SR, et al. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents[J]. Melanoma Res. 2007 Jun;17(3):193-200.
Google Scholar | Crossref | Medline20. Chen, L, Zhu, X, Li, D, et al. Effect of thoracic hyperthermic perfusion with recombinant human endostatin plus nedaplatin in treating pleural effusion in patients with advanced non-small cell lung cancer[J]. J BUON. 2020;25(6):2643-2649.
Google Scholar | Medline21. Wenbin, GAO, Jinyan, LYU, Ruoyu, WANG. Clinical effects and adverse reactions of recombinant human endostatin[J]. Adverse Drug React J. 2007;9(1):32-35.
Google Scholar22. Lin, YANG, Jinwan, WANG, Zhongming, TANG, et al. A phase I clinical trial for recombinant human endostatin[J]. Chin J New Drugs. 2004;13(6):548-553.
Google Scholar23. Wenjing, MENG, Qi, GAO, Liuchun, WANG, et al. Analysis of cardiovascular-related adverse effects of endostar combined with chemotherapy in 61 NSCLC cases[J]. Chin J Lung Cancer. 2009;12(06):577-581.
Google Scholar24. Nair, N . Epidemiology and pathogenesis of heart failure with preserved ejection fraction[J]. Rev Cardiovasc Med. 2020 Dec 30;21(4):531-540.
Google Scholar | Medline25. Shan, R, Liu, N, Yan, Y, et al. Apoptosis, autophagy and atherosclerosis: relationships and the role of Hsp27[J]. Pharmacol Res. 2021 Apr;166:105169.
Google Scholar | Crossref | Medline26. Wang, J, Zhou, H. Mitochondrial quality control mechanisms as molecular targets in cardiac ischemia-reperfusion injury[J]. Acta Pharm Sin B. 2020 Oct;10(10):1866-1879.
Google Scholar | Crossref | Medline27. Qin, J, Zhang, P, Qian, X, et al. Assessment of the cardiotoxicity of recombinant human endostatin using myocardial biochemical markers in cancer patients[J]. Nan Fang Yi Ke Da Xue Xue Bao. 2008 Jun;28(6):930-932.
Google Scholar | Medline28. Kisker, O, Becker, CM, Prox, D, et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model[J]. Cancer Res. 2001 Oct 15;61(20):7669-7674.
Google Scholar | Medline29. Hu, B, Zhu, H, Zhu, L, et al. Bioactivity, pharmacokinetics, and immunogenicity assays in preclinical and clinical trials for recombinant human endostatin[J]. Acta Pharmacol Sin. 2008 Nov;29(11):1357-1369.
Google Scholar | Crossref | Medline30. Boehm, T, Folkman, J, Browder, T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance[J]. Nature. 1997 Nov 27;390(6658):404-407.
Google Scholar | Crossref | Medline31. Dahlberg, SE, Shapiro, GI, Clark, JW, et al. Evaluation of statistical designs in phase I expansion cohorts: the Dana-farber/harvard cancer center experience. J Natl Cancer Inst. 2014 Jun 24;106(7):dju163.
Google Scholar | Medline